Concurrently with these guidelines, NASS developed Appropriate Use Criteria to determine appropriate (or reasonable) ...
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback